Use of Valdoxan (Agomelatin) in the Combined Treatment of Moderate and Severe Nonpsychotic Depression

Author： Medvedev V.  

Publisher： Springer Publishing Company

ISSN： 0097-0549

Source： Neuroscience and Behavioral Physiology, Vol.43, Iss.7, 2013-09, pp. : 878-882

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bodily symptoms in moderate and severe depression

By Nyboe Jacobsen Lene   Smith Lassen Irene   Friis Preben   Videbech Poul   Wentzer Licht Rasmus  

Nordic Journal of Psychiatry, Vol. 60, Iss. 4, 2006-08 ,pp. : 294-298

Informa Healthcare

Access to resources Recommend Favorite

Valdoxan in the Treatment of Depression in Neurological Practice: Results of the Russian Multicenter Naturalistic Study “Resonance”

By Vorob’eva O.  

Neuroscience and Behavioral Physiology, Vol. 43, Iss. 9, 2013-11 ,pp. : 1126-1131

Springer Publishing Company

Access to resources Recommend Favorite

Valdoxan (agomelatine) in the Treatment of Depression in Cerebrovascular Diseases (results of the Russian Resonance multicenter naturalistic study)

By Pizova N.  

Neuroscience and Behavioral Physiology, Vol. 44, Iss. 3, 2014-03 ,pp. : 315-319

Springer Publishing Company

Access to resources Recommend Favorite

Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK

By Borghi J.   Guest J.F.  

European Psychiatry, Vol. 15, Iss. 6, 2000-09 ,pp. : 378-387

Elsevier

Access to resources Recommend Favorite

Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria

By Brown M.C.J.   Nimmerrichter A.A.   Guest J.F.  

European Psychiatry, Vol. 14, Iss. 4, 1999-07 ,pp. : 230-244

Elsevier

Access to resources Recommend Favorite